II
HAE icon

Ibex Investors’s Haemonetics HAE Stock Holding History

Ibex Investors’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2,265
Closed -$226K – 93
2018
Q4 		$226K Buy
+2,265
New +$238K 0.04% 83
2018
Q2 		– Sell
-4,147
Closed -$303K – 197
2018
Q1 		$303K Sell
4,147
-339
-8% -$23.3K 0.25% 94
2017
Q4 		$264K Buy
+4,486
New +$236K 0.15% 41

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Ibex Investors's HAE Position: Q1 2019 in Review

Ibex Investors sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 2,265 shares — an estimated $226K sold.

Ibex Investors first reported a position in HAE in Q4 2017 and held it in 3 quarters. The position peaked at $303K in Q1 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

  • Ibex Investors reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
  • Ibex Investors sold 2,265 Haemonetics shares in Q1 2019, an estimated $226K.
  • Ibex Investors first reported a position in Haemonetics in Q4 2017 and held it in 3 quarters.
  • Ibex Investors's Haemonetics position peaked at $303K in Q1 2018.
  • 260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on Ibex Investors's 13F filing for Q1 2019, filed 7 May 2019.